Current evidence and future research needs for FeNO measurement in respiratory diseases

Leif Bjermer, Kjell Alving, Zuzana Diamant, Helgo Magnussen, Ian Pavord, Giorgio Piacentini, David Price, Nicolas Roche, Joaquin Sastre, Mike Thomas, Omar Usmani

Research output: Contribution to journalArticle

85 Citations (Scopus)
14 Downloads (Pure)

Abstract

Although not yet widely implemented, fraction of exhaled nitric oxide (FeNO) has emerged in recent years as a potentially useful biomarker for the assessment of airway inflammation both in undiagnosed patients with non-specific respiratory symptoms and in those with established airway disease. Research to date essentially suggests that FeNO measurement facilitates the identification of patients exhibiting T-helper cell type 2 (Th2)-mediated airway inflammation, and effectively those in whom anti-inflammatory therapy, particularly inhaled corticosteroids (ICS), is beneficial. In some studies, FeNO-guided management of patients with established airway disease is associated with lower exacerbation rates, improvements in adherence to anti-inflammatory therapy, and the ability to predict risk of future exacerbations or decline in lung function. Despite these data, concerns regarding the applicability and utility of FeNO in clinical practice still remain. This article reviews the current evidence, both supportive and critical of FeNO measurement, in the diagnosis and management of asthma and other inflammatory airway diseases. It additionally provides suggestions regarding the practical application of FeNO measurement: how it could be integrated into routine clinical practice, how its utility could be assessed and its true value to both clinicians and patients could be established. Although some unanswered questions remain, current evidence suggests that FeNO is potentially a valuable tool for improving the personalised management of inflammatory airway diseases.

Original languageEnglish
Pages (from-to)830-841
Number of pages12
JournalRespiratory Medicine
Volume108
Issue number6
Early online date15 Feb 2014
DOIs
Publication statusPublished - Jun 2014

Fingerprint

Nitric Oxide
Anti-Inflammatory Agents
Inflammation
Th2 Cells
Airway Management
Adrenal Cortex Hormones
Asthma
Biomarkers
Lung
Therapeutics
Research

Keywords

  • breath test
  • diagnosis
  • therapy monitoring
  • health economy
  • eosinophil

Cite this

Bjermer, L., Alving, K., Diamant, Z., Magnussen, H., Pavord, I., Piacentini, G., ... Usmani, O. (2014). Current evidence and future research needs for FeNO measurement in respiratory diseases. Respiratory Medicine, 108(6), 830-841. https://doi.org/10.1016/j.rmed.2014.02.005

Current evidence and future research needs for FeNO measurement in respiratory diseases. / Bjermer, Leif; Alving, Kjell; Diamant, Zuzana; Magnussen, Helgo; Pavord, Ian; Piacentini, Giorgio; Price, David; Roche, Nicolas; Sastre, Joaquin; Thomas, Mike; Usmani, Omar.

In: Respiratory Medicine, Vol. 108, No. 6, 06.2014, p. 830-841.

Research output: Contribution to journalArticle

Bjermer, L, Alving, K, Diamant, Z, Magnussen, H, Pavord, I, Piacentini, G, Price, D, Roche, N, Sastre, J, Thomas, M & Usmani, O 2014, 'Current evidence and future research needs for FeNO measurement in respiratory diseases', Respiratory Medicine, vol. 108, no. 6, pp. 830-841. https://doi.org/10.1016/j.rmed.2014.02.005
Bjermer L, Alving K, Diamant Z, Magnussen H, Pavord I, Piacentini G et al. Current evidence and future research needs for FeNO measurement in respiratory diseases. Respiratory Medicine. 2014 Jun;108(6):830-841. https://doi.org/10.1016/j.rmed.2014.02.005
Bjermer, Leif ; Alving, Kjell ; Diamant, Zuzana ; Magnussen, Helgo ; Pavord, Ian ; Piacentini, Giorgio ; Price, David ; Roche, Nicolas ; Sastre, Joaquin ; Thomas, Mike ; Usmani, Omar. / Current evidence and future research needs for FeNO measurement in respiratory diseases. In: Respiratory Medicine. 2014 ; Vol. 108, No. 6. pp. 830-841.
@article{01209517f547474c84cf27a9cfc08c99,
title = "Current evidence and future research needs for FeNO measurement in respiratory diseases",
abstract = "Although not yet widely implemented, fraction of exhaled nitric oxide (FeNO) has emerged in recent years as a potentially useful biomarker for the assessment of airway inflammation both in undiagnosed patients with non-specific respiratory symptoms and in those with established airway disease. Research to date essentially suggests that FeNO measurement facilitates the identification of patients exhibiting T-helper cell type 2 (Th2)-mediated airway inflammation, and effectively those in whom anti-inflammatory therapy, particularly inhaled corticosteroids (ICS), is beneficial. In some studies, FeNO-guided management of patients with established airway disease is associated with lower exacerbation rates, improvements in adherence to anti-inflammatory therapy, and the ability to predict risk of future exacerbations or decline in lung function. Despite these data, concerns regarding the applicability and utility of FeNO in clinical practice still remain. This article reviews the current evidence, both supportive and critical of FeNO measurement, in the diagnosis and management of asthma and other inflammatory airway diseases. It additionally provides suggestions regarding the practical application of FeNO measurement: how it could be integrated into routine clinical practice, how its utility could be assessed and its true value to both clinicians and patients could be established. Although some unanswered questions remain, current evidence suggests that FeNO is potentially a valuable tool for improving the personalised management of inflammatory airway diseases.",
keywords = "breath test , diagnosis, therapy monitoring, health economy, eosinophil",
author = "Leif Bjermer and Kjell Alving and Zuzana Diamant and Helgo Magnussen and Ian Pavord and Giorgio Piacentini and David Price and Nicolas Roche and Joaquin Sastre and Mike Thomas and Omar Usmani",
note = "Copyright {\circledC} 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.",
year = "2014",
month = "6",
doi = "10.1016/j.rmed.2014.02.005",
language = "English",
volume = "108",
pages = "830--841",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Current evidence and future research needs for FeNO measurement in respiratory diseases

AU - Bjermer, Leif

AU - Alving, Kjell

AU - Diamant, Zuzana

AU - Magnussen, Helgo

AU - Pavord, Ian

AU - Piacentini, Giorgio

AU - Price, David

AU - Roche, Nicolas

AU - Sastre, Joaquin

AU - Thomas, Mike

AU - Usmani, Omar

N1 - Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

PY - 2014/6

Y1 - 2014/6

N2 - Although not yet widely implemented, fraction of exhaled nitric oxide (FeNO) has emerged in recent years as a potentially useful biomarker for the assessment of airway inflammation both in undiagnosed patients with non-specific respiratory symptoms and in those with established airway disease. Research to date essentially suggests that FeNO measurement facilitates the identification of patients exhibiting T-helper cell type 2 (Th2)-mediated airway inflammation, and effectively those in whom anti-inflammatory therapy, particularly inhaled corticosteroids (ICS), is beneficial. In some studies, FeNO-guided management of patients with established airway disease is associated with lower exacerbation rates, improvements in adherence to anti-inflammatory therapy, and the ability to predict risk of future exacerbations or decline in lung function. Despite these data, concerns regarding the applicability and utility of FeNO in clinical practice still remain. This article reviews the current evidence, both supportive and critical of FeNO measurement, in the diagnosis and management of asthma and other inflammatory airway diseases. It additionally provides suggestions regarding the practical application of FeNO measurement: how it could be integrated into routine clinical practice, how its utility could be assessed and its true value to both clinicians and patients could be established. Although some unanswered questions remain, current evidence suggests that FeNO is potentially a valuable tool for improving the personalised management of inflammatory airway diseases.

AB - Although not yet widely implemented, fraction of exhaled nitric oxide (FeNO) has emerged in recent years as a potentially useful biomarker for the assessment of airway inflammation both in undiagnosed patients with non-specific respiratory symptoms and in those with established airway disease. Research to date essentially suggests that FeNO measurement facilitates the identification of patients exhibiting T-helper cell type 2 (Th2)-mediated airway inflammation, and effectively those in whom anti-inflammatory therapy, particularly inhaled corticosteroids (ICS), is beneficial. In some studies, FeNO-guided management of patients with established airway disease is associated with lower exacerbation rates, improvements in adherence to anti-inflammatory therapy, and the ability to predict risk of future exacerbations or decline in lung function. Despite these data, concerns regarding the applicability and utility of FeNO in clinical practice still remain. This article reviews the current evidence, both supportive and critical of FeNO measurement, in the diagnosis and management of asthma and other inflammatory airway diseases. It additionally provides suggestions regarding the practical application of FeNO measurement: how it could be integrated into routine clinical practice, how its utility could be assessed and its true value to both clinicians and patients could be established. Although some unanswered questions remain, current evidence suggests that FeNO is potentially a valuable tool for improving the personalised management of inflammatory airway diseases.

KW - breath test

KW - diagnosis

KW - therapy monitoring

KW - health economy

KW - eosinophil

U2 - 10.1016/j.rmed.2014.02.005

DO - 10.1016/j.rmed.2014.02.005

M3 - Article

VL - 108

SP - 830

EP - 841

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 6

ER -